Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ERS congress

- PMLiVE

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

AZ buys into ADC sector with $440m Spirogen deal

Pushes into the market for antibody-drug conjugates

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

AstraZeneca advertises Crestor with ‘fun’ TV spot

TV campaign compares choice of medicine over Lipitor to sporting rivalry

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

- PMLiVE

New arrivals join BioHub at AZ’s Alderley Park

Six new biopharma start-ups set up at the UK biocluster

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

FDA to review AZ’s fish oil drug Epanova

Hypertriglyceridaemia treatment acquired as part of Omthera takeover

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links